Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.32 |
| ▸ | BCHE | P06276 | 3/20 | 0.31 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27813326 | 0.78 | BTK (0.38) | BTKHSD11B1EPHX1CHRM3BCHE | |
| SCHEMBL8737769 | 0.78 | HDAC6 (0.39) | HSD11B1SMN1; SMN2 | |
| SCHEMBL19133124 | 0.77 | NAAA (0.37) | HSD11B1CYP19A1EPHX1BCHECACNA1B | |
| SCHEMBL20763031 | 0.77 | CYP19A1 (0.35) | BTKHSD11B1CYP19A1EPHX1CHRM3 | |
| SCHEMBL22068055 | 0.77 | CYP19A1 (0.35) | BTKHSD11B1CYP19A1EPHX1CHRM3 | |
| SCHEMBL26664320 | 0.76 | BTK (0.35) | BTKHSD11B1EPHX1CHRM3HPGD | |
| SCHEMBL9873641 | 0.76 | HDAC6 (0.36) | — | |
| Adamantane SCHEMBL135442 | 0.75 | HSD11B1 (0.43) | BTKHSD11B1CHRM3CHRM2CHRM1 | |
| SCHEMBL15565387 | 0.75 | EPHX1 (0.37) | EPHX1CHRM3BCHECHRM1NAAA | |
| SCHEMBL26635790 | 0.75 | BTK (0.39) | BTKCYP19A1EPHX1CHRM3CACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12384790-B2 | Pteridinone compounds and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-08-12 | — | — | US | disclosed |
| EP-3784669-B1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMA (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-05 | — | — | US | disclosed |
| US-20220363685-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2022-11-17 | — | — | US | disclosed |
| EP-3784669-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2021-03-03 | — | — | EP | disclosed |
| CN-102112467-B | Pyrimidine derivative as kinase inhibitors | IRM LLC | 2014-04-30 | — | — | CN | disclosed |
| CN-102762549-A | Phthalazinone derivative, and preparation method and pharmaceutical use thereof | SHANGHAI HENGRUI PHARM CO LTD | 2012-10-31 | — | — | CN | disclosed |
| CN-102372698-A | Phthalazinone derivative and its preparation method and use in medicine | JIANGSU HENGRUI MEDICINE CO | 2012-03-14 | — | — | CN | disclosed |
| CN-102112467-A | Compounds and compositions as kinase inhibitors | IRM LLC | 2011-06-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363685-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | BTK 2261/4885HSD11B1 417/4885CYP19A1 186/4885 |
| US-20230312587-A1 | PTERIDINONE COMPOUNDS AND USES THEREOF | DPYD, PKD1, TYMP | BTK 2261/4885HSD11B1 417/4885CYP19A1 186/4885 |
| US-12384790-B2 | Pteridinone compounds and uses thereof | DPYD, PKD1, TYMP | BTK 2261/4885HSD11B1 417/4885CYP19A1 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.